Comparison of circulating biomarkers among PHIVAYA subgroups. by Maria Raffaella Petrara (4446358)

Comparison of HIV-DNA and cell-associated HIV-RNA levels among PHIVAYA subgroups. by Maria Raffaella Petrara (4446358)

Comparison of immune and cellular markers of aging among PHIVAYA subgroups. by Maria Raffaella Petrara (4446358)

Gaussian model fitted of the number of dogs detections of SARS-CoV-2, depending on the cycle threshold (Ct) values of RT-qPCR tests for SARS-CoV-2. by Víctor M. Vidal-Martínez (18707335)

Schematic pathogenetic pathway of how persistent HIV reservoir may lead to premature aging and precocious onset of aging-related comorbidities. by Maria Raffaella Petrara (4446358)

Calibration of standards. by Asif Khan (1740271)

“…<i>erecta</i> may be a promising medicinal agent for reducing the risk and progression of Parkinson’s disease.…”

Appearance of standards under UV 365 nm. by Asif Khan (1740271)

“…<i>erecta</i> may be a promising medicinal agent for reducing the risk and progression of Parkinson’s disease.…”

HPLC-Chromatogram of methanol fraction. by Asif Khan (1740271)

“…<i>erecta</i> may be a promising medicinal agent for reducing the risk and progression of Parkinson’s disease.…”

Effects of <i>B</i>.<i>erecta</i> on kidney profile test. by Asif Khan (1740271)

“…<i>erecta</i> may be a promising medicinal agent for reducing the risk and progression of Parkinson’s disease.…”

Effects of <i>B</i>.<i>erecta</i> on Morris water maze test. by Asif Khan (1740271)

“…<i>erecta</i> may be a promising medicinal agent for reducing the risk and progression of Parkinson’s disease.…”

Effects of <i>B</i>.<i>erecta</i> on liver profile test. by Asif Khan (1740271)

“…<i>erecta</i> may be a promising medicinal agent for reducing the risk and progression of Parkinson’s disease.…”

Antibody reagent list. by Helena Saura Martinez (22305113)

“…In <i><i>T. bryosalmonae</i></i> exposed animals, parasite concentration increased significantly over time. Moreover, a proportional increase in IgM⁺ B cells and a proportional decrease in myeloid cells over time was observed. …”

Age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Estimated annual percentage changes in the prevalence rate of specific gynecological diseases from 1990 to 2021, categorized by age group and SDI. by Xiaofeng He (2618752)

Prevalence and trends of gynecological diseases (GDs) among women of childbearing age, by age group and SDI. by Xiaofeng He (2618752)

Prevalence of gynecological diseases (GDs) among women of childbearing age in 2021, along with their changes from 1990 to 2021, and the contribution of each GD to the overall preva... by Xiaofeng He (2618752)

A) Expression of known ‘tendon’ transcription factors, B) TGFβ and C) ECM genes measured with RNA-seq. by Heather L. Dingwall (14573796)

“…Expression of ECM related genes are significantly differentially expressed in unique directions during postnatal stages with <i>Dcn</i> and <i>Fmod</i> increasing gradually over time, <i>Col2a1</i>, <i>Col14a1</i>, <i>Col3a1</i>, and <i>Tnmd</i> decreasing over time, <i>Col1a1</i> and <i>Col1a2</i> peak in expression at P14, and <i>Bgn</i> is expressed at higher levels from P0-P14 after which its levels decrease (C). …”

Changes in relative abundance of genera in both therapeutic groups. by Flavia Furlaneto (20161022)

“…Negative values refer to reduction in abundance after treatment (Mann-Whitney test, a, p = 0.049; b, p = 0.001; c, p = 0.006). For instance, <i>Catonella</i> had a median increase of 35.5% in the probiotic group compared to a median reduction of 52% in the placebo. …”

Flowchart of the study. by Flavia Furlaneto (20161022)

“…The Probiotic group had a lower percentage of BOMP when compared with the Placebo group at 8 weeks (<i>p</i><0.0001). …”